Beth Hecht sold $124k of XERS
See Remarks at Xeris Biopharma Holdings, Inc.. 16,667 shares at an average of $7.45, traded Feb 2, 2026, filed Feb 2, 2026.
Score components
- +15RoleOfficer
- +10Trade size$124k at market
- 0Share of holdings soldSold 1.3% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -17.5%, 3m -13.9%, 6m +10.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001652410-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 30, 2026 | AGrant or award Common Stock | +121,293 | $0.00 | $0 | 1,429,396 | Feb 2, 2026 |
| Jan 31, 2026 | FTax withholding Common Stock | -98,375 | $7.36 | $724k | 1,331,021 | Feb 2, 2026 |
| Jan 31, 2026 | FTax withholding Common Stock | -46,914 | $7.36 | $345k | 1,284,107 | Feb 2, 2026 |
| Jan 31, 2026 | FTax withholding Common Stock | -24,266 | $7.36 | $179k | 1,259,841 | Feb 2, 2026 |
| Feb 2, 2026 | SOpen-market sale Common Stock10b5-1 | -16,667 | $7.45 | $124k | 1,243,174 | Feb 2, 2026 |
| Jan 30, 2026 | AGrant or award Stock Option (Right to Buy)derivative | +162,162 | $0.00 | $0 | 162,162 | Feb 2, 2026 |
Related signals
Other insiders at Xeris Biopharma Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | Xeris Biopharma Holdings, Inc. | Beth Hecht See Remarks | $157k 16,666 shares | -1% | |
| 21Weak | Xeris Biopharma Holdings, Inc. | Kevin McCulloch See Remarks | $141k 15,000 shares | -1% | |
| 16Weak | Xeris Biopharma Holdings, Inc. | Steven Pieper See Remarks | $47k 5,000 shares | -0% | |
| 23Weak | Xeris Biopharma Holdings, Inc. | Kevin McCulloch See Remarks | $250k 25,000 shares | -2% | |
| 21Weak | Xeris Biopharma Holdings, Inc. | Beth Hecht See Remarks | $141k 16,666 shares | -1% | |
| 21Weak | Xeris Biopharma Holdings, Inc. | Kevin McCulloch See Remarks | $127k 15,000 shares | -1% | |
| 16Weak | Xeris Biopharma Holdings, Inc. | Steven Pieper See Remarks | $43k 5,000 shares | -0% | |
| 16Weak | Xeris Biopharma Holdings, Inc. | Steven Pieper See Remarks | $43k 5,000 shares | -0% | |
| 21Weak | Xeris Biopharma Holdings, Inc. | Beth Hecht See Remarks | $134k 16,666 shares | -1% | |
| 20Weak | Xeris Biopharma Holdings, Inc. | Kevin McCulloch See Remarks | $120k 15,000 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.